The fact that, in this trial, the primary endpoint did not reach statistical significance for the whole population of randomised patients might be explained, at least partially, as follows: the ~60% of patients not using SABA during the baseline period had their asthma sufficiently controlled by ICS alone, so that asthma exacerbations did not occur, even when ICS were reduced or withdrawn, thanks to a carryover effect of the latter [ 110 , 112 ].
1
—
—